About: Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase
Creator	Falahati, Mojtaba Sharifi, Majid Babadaei, Nejadi Haghighat, Setareh Haj Bloukh, Samir Hasan, Anwarul Kachooei, Ehsan Mahdi, Mohammad Vahdani, Yasaman
source	Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative representative of a severe respiratory illness resulted in widespread human infections and deaths in nearly all of the countries since late 2019. There is no therapeutic FDA-approved drug against SARS-CoV-2 infection, although a combination of anti-viral drugs is directly being practiced in some countries. A broad-spectrum of antiviral agents are being currently evaluated in clinical trials, and in this review, we specifically focus on the application of Remdesivir (RVD) as a potential anti-viral compound against Middle East respiratory syndrome (MERS) -CoV, SARS-CoV and SARS-CoV-2. First, we overview the general information about SARS-CoV-2, followed by application of RDV as a nucleotide analogue which can potentially inhibits RNA-dependent RNA polymerase of COVs. Afterwards, we discussed the kinetics of SARS- or MERS-CoV proliferation in animal models which is significantly different compared to that in humans. Finally, some ongoing challenges and future perspective on the application of RDV either alone or in combination with other anti-viral agents against CoVs infection were surveyed to determine the efficiency of RDV in preclinical trials. As a result, this paper provides crucial evidence of the potency of RDV to prevent SARS-CoV-2 infections. Communicated by Ramaswamy H. Sarma
has issue date	2020-05-20(xsd:dateTime)
bibo:doi	10.1080/07391102.2020.1767210
bibo:pmid	32397906
has license	no-cc
sha1sum (hex)	41eaa91ed988209f44b12d82accde002481f4924
schema:url	https://doi.org/10.1080/07391102.2020.1767210
resource representing a document's title	Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase
has PubMed Central identifier	PMC7256352
has PubMed identifier	32397906
schema:publication	J Biomol Struct Dyn
resource representing a document's body	covid:41eaa91ed988209f44b12d82accde002481f4924#body_text
is schema:about of	named entity 'preclinical trials' named entity 'evidence' named entity 'remdesivir' named entity 'PRACTICED' named entity 'POTENTIAL' named entity 'RNA-DEPENDENT RNA POLYMERASE' named entity 'WIDESPREAD' named entity 'OVERVIEW' named entity 'PROVIDES' named entity 'FUTURE' covid:arg/41eaa91ed988209f44b12d82accde002481f4924 named entity 'humans' named entity 'potency' named entity 'First' named entity 'future' named entity 'focus' named entity 'potential' named entity '2019' named entity 'kinetics' named entity 'human' named entity 'respiratory illness' named entity 'FDA-approved' named entity 'Remdesivir' named entity 'preclinical trials' named entity 'antiviral agents' named entity 'anti-viral drugs' named entity 'anti-viral' named entity 'nucleotide analogue' named entity 'Middle East respiratory syndrome' named entity 'SARS-CoV-2' named entity 'RNA dependent RNA polymerase' named entity 'COVID-19' named entity 'RNA genome' named entity 'viruses' named entity 'virus replication' named entity 'viruses' named entity 'MERS' named entity 'SARS' named entity 'MERS-CoV' named entity 'anti-viral' named entity 'WHO' named entity 'angiotensin-converting enzyme 2' named entity 'oritavancin' named entity 'synergistic' named entity 'animal model' named entity 'epidemics' named entity 'animal models' named entity 'MERS-CoV' named entity 'respiratory problems' named entity 'SARS-CoV' named entity 'ExoN' named entity 'SARS' named entity 'higher risk' named entity 'virus' named entity 'laboratory experimentation' named entity 'titer' named entity 'infection' named entity 'SARS-CoV-2' named entity 'virus' named entity 'virus' named entity 'treating SARS' named entity 'ACE2' named entity 'anti-viral drug' named entity 'viral replication' named entity 'ExoN' named entity 'SARS' named entity 'COVID' named entity 'interferon' named entity 'genome' named entity 'pandemics' named entity 'clinical trials' named entity 'anti-viral' named entity 'MERS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software